Galapagos NV (GLPG)

Price$27.73

Value ScoreA

Growth ScoreB

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-21.35%

Price vs S&P 500 (4W)4.28%

VGM Score65.91

Market Capitalization$1.84B

P/E Ratio (Annual)4.95x

All Metrics

Book Value / Share (Quarterly)$56.79

P/TBV (Annual)0.57x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)26.30%

Cash Flow / Share (Quarterly)$-4.76

Price vs S&P 500 (YTD)0.77%

Gross Margin (TTM)98.98%

Net Profit Margin (TTM)71.04%

EPS (TTM)$8.58

10-Day Avg Trading Volume0.06M

EPS Excl Extra (TTM)$8.58

Revenue Growth (5Y)15.97%

EPS (Annual)$5.63

ROI (Annual)9.90%

Gross Margin (Annual)97.33%

Net Profit Margin (5Y Avg)13.47%

Cash / Share (Quarterly)$52.62

P/E Basic Excl Extra (TTM)3.25x

Revenue Growth QoQ (YoY)-91.36%

P/E Normalized (Annual)4.95x

ROA (Last FY)9.42%

Revenue Growth TTM (YoY)81.33%

EBITD / Share (TTM)$8.47

ROE (5Y Avg)1.50%

Operating Margin (TTM)65.44%

Cash Flow / Share (Annual)$-4.76

P/B Ratio0.49x

P/B Ratio (Quarterly)0.57x

Net Income / Employee (Annual)$820,995

EV / Revenue (TTM)1.48x

Net Interest Coverage (TTM)-1.68x

ROA (TTM)8.70%

EPS Growth QoQ (YoY)3033.03%

EV / EBITDA (TTM)3.98x

EPS Incl Extra (Annual)$5.63

Current Ratio (Annual)20.15x

Quick Ratio (Quarterly)20.00x

3-Month Avg Trading Volume0.06M

52-Week Price Return-2.17%

P/E Incl Extra (TTM)3.25x

Revenue / Employee (TTM)$2,488,426

Tangible BV / Share (Quarterly)$56.77

P/S Ratio (Annual)1.43x

Asset Turnover (Annual)0.33x

52-Week High$24.56

Operating Margin (5Y Avg)-23.65%

EPS Excl Extra (Annual)$5.63

CapEx CAGR (5Y)-31.41%

Tangible BV CAGR (5Y)4.44%

26-Week Price Return-13.20%

Quick Ratio (Annual)20.00x

13-Week Price Return-18.18%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)20.15x

Enterprise Value$1.78B

Revenue / Share Growth (5Y)15.68%

Asset Turnover (TTM)0.28x

Book Value / Share Growth (5Y)3.76%

Revenue / Employee (Annual)$2,845,783

Inventory Turnover (Annual)0.81x

Pretax Margin (Annual)27.05%

Cash / Share (Annual)$52.62

3-Month Return Std Dev27.17%

Gross Margin (5Y Avg)89.02%

Net Income / Employee (TTM)$1,250,632

ROE (Last FY)9.92%

Net Interest Coverage (Annual)-1.20x

EPS Basic Excl Extra (Annual)$5.63

Receivables Turnover (TTM)30.54x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$8.58

Receivables Turnover (Annual)50.25x

ROI (TTM)11.55%

P/S Ratio (TTM)1.63x

Pretax Margin (5Y Avg)-1.53%

Revenue / Share (Annual)$19.52

Tangible BV / Share (Annual)$56.77

Price vs S&P 500 (52W)-32.71%

P/E Ratio (TTM)3.25x

EPS Growth TTM (YoY)331.50%

Year-to-Date Return1.58%

5-Day Price Return2.52%

EPS Normalized (Annual)$5.63

ROA (5Y Avg)1.90%

Net Profit Margin (Annual)28.85%

Month-to-Date Return-0.25%

Cash Flow / Share (TTM)$-3.32

EBITD / Share (Annual)$6.15

Operating Margin (Annual)26.53%

LT Debt / Equity (Annual)0.58x

ROI (5Y Avg)1.51%

P/E Excl Extra (TTM)3.25x

LT Debt / Equity (Quarterly)0.32x

EPS Basic Excl Extra (TTM)$8.58

P/TBV (Quarterly)0.57x

P/B Ratio (Annual)0.57x

Inventory Turnover (TTM)0.81x

Pretax Margin (TTM)71.22%

Book Value / Share (Annual)$56.79

Price vs S&P 500 (13W)-27.04%

Beta0.42x

P/FCF (Annual)0.54x

Revenue / Share (TTM)$17.08

ROE (TTM)11.59%

52-Week Low$22.62

vGradeA

gGradeB

mGradeC

vgmGradeB

Show chart for

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

2.61

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
GLPGGalapagos NV	A	B	C	$27.73
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Galapagos NV is a fully integrated biotechnology company developing medicines for oncology and immunology, with operations in Europe and the United States. Its pipeline includes CAR-T cell therapies for blood cancers and a TYK2 inhibitor for autoimmune diseases currently in Phase 2 development. The company generates the majority of its revenue from the United States market.